77 trends tracked about this subject — the full history, oldest to newest below.
Moderna CEO Stéphane Bancel says the company's personalized mRNA cancer vaccine could work in "more cancers than melanoma" and aims for FDA approval by 2027, with shares up 750% in 2026.
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Moderna returns to profit, lifts its financial outlook, and reaches a five-year stock high as COVID-19 vaccine demand stabilizes.
Moderna swings to a profit as momentum builds for its cancer vaccine, according to financial reports.
Moderna raises its 2026 outlook and swings to a profit as newer vaccines and cancer treatments gain traction.
13 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Moderna and Merck's mRNA cancer vaccine reduces melanoma recurrence by 42% according to recent coverage.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Moderna's cancer vaccine shows a 42% reduction in melanoma recurrence in Phase 3 trial data leaked prior to ESMO.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
A personalized mRNA cancer vaccine developed by Moderna and Merck cuts melanoma recurrence or death risk by 42%.
Moderna stock extends recent market losses following the release of trial data concerning a novel mRNA melanoma vaccine.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Personalized mRNA cancer vaccine data shows significant reduction in melanoma recurrence and death rates.
Moderna has initiated a late-stage trial for an mRNA bird flu vaccine amid broader developments in influenza immunization options.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Moderna shares tumble following a reported leak of cancer vaccine data involving melanoma treatments.
Older adults and pharmacies navigate new mRNA options and availability questions for the current flu season.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
New developments in personalized mRNA cancer vaccines show promise for melanoma and breast cancer, though hurdles in public perception remain.
Moderna shares surge and track toward top September S&P 500 performance as markets eye upcoming clinical data.
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
The US has seen the launch of Moderna's mFlusiva, the first approved mRNA flu vaccine designed for specific older adult populations.
Recent coverage examines the growing cancer vaccines market alongside Phase 3 mRNA vaccine results and personalised medicine strategies.
Moderna shares surge toward a 52-week high as upcoming melanoma vaccine data commands attention at the ESMO Congress.
Moderna's first mRNA flu vaccine has received FDA approval and is now available for older adults ahead of the 2026 flu season.
Dow futures point to a rebound in S&P 500 and Nasdaq above key levels, while Moderna, AMD and SpaceX flash buy signals spark trader interest.
A newly approved mRNA flu shot for adults 50+ is rolling out at CVS, Walgreens and local pharmacies as the 2026 flu season approaches.
Dow Jones futures face pressure as anticipation of a Federal Reserve rate hike coincides with rising oil prices and yields.
Moderna and Merck trial data sparks debate over whether a personalized medicine revolution is beginning.
Health coverage highlights FDA approval of Moderna's new mRNA flu vaccine and emerging studies on broader antibody responses.
Personalized mRNA cancer vaccines are gaining momentum following Phase III success in melanoma and expanded global clinical trials.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
GSK advances its mRNA flu vaccine candidate to phase 3 trials following successful mid-stage performance data.
GSK is advancing a new mRNA flu vaccine to Phase III trials after the candidate outperformed standard vaccinations in earlier testing.
Wall Street closed August with gains driven by an unusual set of winners and a continued recovery within the software industry.
BioNTech and Genentech have terminated a phase 2 mRNA colorectal cancer vaccine trial after safety reviews revealed more deaths than in the control group.
FDA clears new Moderna and XFG‑Adapted COVID shots for fall 2026 as cases climb, prompting fresh media focus on seasonal protection.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Moderna and Merck have reported a significant triumph regarding a collaborative cancer vaccine trial that could revolutionize oncology treatment.
The FDA has approved Moderna's mRNA-based flu vaccine, marking a shift in immunization technology for older adults.
Advancements in mRNA technology are driving the development of cancer vaccines, specifically targeting melanoma and expanding medical breakthroughs.
11 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Moderna and Merck's mRNA melanoma vaccine is drawing significant attention as a potential game changer according to recent coverage.
Recent trial results for an mRNA vaccine developed by Moderna point toward a potential shift in future cancer care.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.